Butantan-DV is Brazil's first nationally-developed dengue vaccine, tested exclusively in Brazilian centers including UFMT's hospital and medical school. The five-year study tracked 1,300 volunteers in Mato Grosso, maintaining over 90% participation and demonstrating 74.4% efficacy in preventing dengue cases.
G1
· Nov 27, 2025
· health
· 2 min de leitura
High
Apuração: Verificado
Brazil's first single-dose dengue vaccine developed with Mato Grosso clinical trials
Mato Grosso has recorded 21 confirmed dengue deaths and 14 additional deaths under investigation in 2025, with women representing 55% of suspected cases.
◉
Health & Medicine
2722 artigos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% correspondência
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% correspondência
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% correspondência
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% correspondência
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% correspondência
Cobertura Relacionada
G1 · Aug 19
Macaé mobiliza 45 salas para atualizar vacinação de menores de 15 anos
Macaé lança campanha de atualização vacinal para menores de 15 anos em 45 pontos de saúde até 1º de setembro, com Dia D …
Agência FAPESP · Aug 19 Pesquisadores desenvolvem vacina inteligente contra chikungunya com vírus que se replica apenas uma vezCientistas da USP criaram uma vacina inovadora contra chikungunya usando vírus geneticamente modificado que se replica a…
G1 · Aug 19 Pastor belga do Senado é afastado após atacar veterinária que segue em estado graveVeterinária terceirizada sofre ataque grave de pastor belga malinois no Senado Federal em Brasília, com mordida no pesco…
Rádio Pampa · Aug 19 Heterossexuais são maioria entre pacientes que descobrem HIV em estágio avançadoEstudo em hospital de Porto Alegre revela que 84% dos pacientes diagnosticados com HIV em estágio avançado são heterosse…
Viés e Enquadramento
⚖
Article presents Brazil's single-dose dengue vaccine development with minimal bias, using factual reporting and institutional attribution, though lacks critical evaluation of efficacy claims or alternative perspectives.
Bias Direction
center
Confidence
MED
Institutional achievement narrative - frames the vaccine development as a national scientific success story, emphasizing Brazilian innovation and institutional contributions. Uses direct quotes from researchers to establish credibility and legitimacy.
100% nacional (100% national) - nationalist framing
primeira vacina de dose única contra a dengue no mundo (world's first single-dose dengue vaccine) - superlative emphasis
feito (feat/achievement) - celebratory language
graças ao esforço da equipe (thanks to team effort) - heroic framing
Independent health experts or international vaccine researchers evaluating the 74.4% efficacy claim
Cost-effectiveness analysis or comparison with existing multi-dose vaccines
Potential side effects or safety concerns beyond the clinical trial data
Perspectives from competing vaccine manufacturers or alternative dengue prevention approaches
Public health implementation challenges or equity concerns regarding age restrictions (12-59 years)
Impacto Geopolítico
🌎
Brazil's Butantan Institute develops world's first single-dose dengue vaccine with 74.4% efficacy, positioning Brazil as a global health innovator and potential vaccine exporter in a disease affecting 390M annually.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Southeast Asia
Sub-Saharan Africa
Global South
Brazil strengthens soft power and scientific diplomacy through indigenous vaccine development, reducing dependence on foreign pharmaceutical companies and establishing potential leadership in tropical disease solutions. This enhances Brazil's standing in global health governance and BRICS health cooperation frameworks.
Similar to India's polio vaccine success (OPV) in the 1990s, which elevated India's biotech sector and global health influence while addressing a regional health crisis.
Lente Econômica
📈
Brazil's Butantan Institute developed the world's first single-dose dengue vaccine with 74.4% efficacy, expected to enter public health system by December 2025, potentially reducing healthcare costs and disease burden.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and biotechnology
Public health and healthcare services
Medical research and development
Tourism and hospitality
Insurance and healthcare administration
Consumers benefit from improved dengue prevention with convenient single-dose administration, potentially reducing out-of-pocket healthcare costs, hospitalizations, and lost productivity. Increased vaccination rates expected due to higher compliance with single-dose regimen.
Government will need to allocate SUS budget for vaccine distribution and mass immunization campaigns starting 2026. Potential regulatory precedent for single-dose vaccine approvals. May influence international vaccine procurement policies and strengthen Brazil's biotech sector positioning. Possible expansion of vaccine coverage age groups based on efficacy data.